CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
Original article

XYNTHA

XYNTHANeutral
AI Analysis

Summary

XYNTHA is a recombinant antihemophilic factor approved for hemophilia A treatment, including on-demand bleeding control, perioperative management, and routine prophylaxis in adults and children.

Importance:1/10
Sentiment:
0.00
hemophilia Arecombinant factorprophylaxis

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on July 6, 2026 6:01 PM

Read Original